Treatments of inflammatory bowel disease toward personalized medicine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ki-Uk | - |
dc.contributor.author | Kim, Jisu | - |
dc.contributor.author | Kim, Wan-Hoon | - |
dc.contributor.author | Min, Hyeyoung | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.date.accessioned | 2021-11-24T03:40:09Z | - |
dc.date.available | 2021-11-24T03:40:09Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/51805 | - |
dc.description.abstract | Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disease characterized by intestinal inflammation and epithelial injury. For the treatment of IBD, 5-aminosalicylic acids, corticosteroids, immunomodulators, and biologic agents targeting tumor necrosis factor (TNF)-alpha, alpha 4 beta 7-integrin, and interleukin (IL)-12/23 have been widely used. Especially, anti-TNF-alpha antibodies are the first biologic agents that presently remain at the forefront. However, 10-30% of patients resist biologic agents, including anti-TNF-alpha agents (primary non-responder; PNR), and 20-50% of primary responders develop treatment resistance within one year (secondary loss of response; SLR). Nonetheless, the etiologies of PNR and SLR are not clearly understood, and predictors of response to biologic agents are also not defined yet. Numerous studies are being performed to discover prediction markers of the response to biologic agents, and this review will introduce currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR. | - |
dc.format.extent | 17 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Treatments of inflammatory bowel disease toward personalized medicine | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-021-01318-6 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.44, no.3, pp 293 - 309 | - |
dc.identifier.kciid | ART002717859 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000632347200001 | - |
dc.identifier.scopusid | 2-s2.0-85103186980 | - |
dc.citation.endPage | 309 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 293 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 44 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Inflammatory bowel disease | - |
dc.subject.keywordAuthor | Ulcerative colitis | - |
dc.subject.keywordAuthor | Crohn&#8217 | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | Personalized medicine | - |
dc.subject.keywordAuthor | Biologic agent | - |
dc.subject.keywordPlus | GENOME-WIDE ASSOCIATION | - |
dc.subject.keywordPlus | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | - |
dc.subject.keywordPlus | NECROSIS-FACTOR INHIBITORS | - |
dc.subject.keywordPlus | ANTI-TNF TREATMENT | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | INFLIXIMAB THERAPY | - |
dc.subject.keywordPlus | CLINICAL-COURSE | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | SUSCEPTIBILITY LOCI | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.